

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 39, 40 and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

94140

<p>Licensee</p> <p>1. Edward W. Sparrow Hospital</p> <p>2. 1215 East Michigan Avenue Lansing, MI 48909-9986</p>		<p>In accordance with letter dated October 9, 1992</p> <p>3. License number 21-01430-01 is amended in its entirety to read as follows:</p>	
		<p>4. Expiration date June 30, 1994</p>	
		<p>5. Docket or Reference No 030-02009</p>	
<p>6. Byproduct, source, and/or special nuclear material</p>		<p>7. Chemical and/or physical form</p>	
<p>8. Maximum amount that licensee may possess at any one time under this license</p>			
A. Any byproduct material identified in 10 CFR 35.100	A. Any radiopharmaceuti- cal identified in 10 CFR 35.100	A. As needed	
B. Any byproduct material identified in 10 CFR 35.200	B. Any radiopharmaceuti- cal identified in 10 CFR 35.200	B. As needed	
C. Any byproduct material identified in 10 CFR 35.300	C. Any radiopharmaceuti- cal identified in 10 CFR 35.300	C. As needed	
D. Any byproduct material identified in 10 CFR 35.400	D. Any brachytherapy source identified in 10 CFR 35.400	D. As needed	
E. Any byproduct material identified in 10 CFR 35.500	E. Sealed sources identified in 10 CFR 35.500	E. As needed	
F. Any byproduct material identified in 10 CFR 31.11	F. Prepackaged Kits	F. As needed	

9307260019 921102
PDR ADOCK 03002009
C PDR

COPY

2
mk 34pd

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License number
21-01430-01

Docket or Reference number
030-02009

Amendment No. 63

- | | | |
|---|----------------------------------|--|
| 6. Byproduct, source, and/or special nuclear material | 7. Chemical and/or physical form | 8. Maximum amount that licensee may possess at any one time under this license |
| G. Uranium depleted in Uranium-235 | G. Cadmium plated metal | G. As needed |
| H. Chromium-51 | H. Any | H. 10 millicuries |
| I. Phosphorus-32 | I. Any | I. 10 millicuries |

9. Authorized Use:

- A. Medical use described in 10 CFR 35.100.
- B. Medical use described in 10 CFR 35.200.
- C. Medical use described in 10 CFR 35.300.
- D. Medical use described in 10 CFR 35.400.
- E. Medical use described in 10 CFR 35.500 in devices which have been evaluated and approved for licensing purposes by the U.S. Nuclear Regulatory Commission or an Agreement State.
- F. In-vitro studies.
- G. Shielding in a linear accelerator.
- H. In-vitro studies.
- I. In-vitro studies.

CONDITIONS

- 10. Location of Use: 1215 East Michigan Avenue, Lansing, Michigan.
- 11. Radiation Safety Officer: Subhash Sharma, Ph.D.

COPY

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number
21-01430-01

Docket or Reference number
030-02009

Amendment No. 63

12. Authorized Users:

- A. J. C. Spencer, M.D., for material in 10 CFR 35.100, 35.200, 35.300, 35.400, 35.500 and 31.11.
- B. R. E. Bethards, M.D., for material in 10 CFR 35.100, 35.200, 35.300, 35.400, 35.500 and 31.11.
- C. Robert E. Brantley, M.D., for material in 10 CFR 35.100, 35.200, 35.300, 35.500 and 31.11.
- D. Lawrence R. Simson, Jr., M.D., for material in 10 CFR 35.100, 35.200, 35.300, 35.500, 31.11 and Chromium-51 for in-vitro studies.
- E. Woon-Man Chung, M.D., for material in 10 CFR 35.100, 35.200 and 35.500.
- F. John Richard Kateley, Ph.D., for material in 10 CFR 31.11, and phosphorus-32 for in-vitro studies.
- G. David A. Krause, M.D., for material in 10 CFR 35.100, 35.200, 35.300, 35.400, 35.500 and 31.11.
- H. James G. Herman, M.D., for material in 10 CFR 35.300, 35.400 and 35.500.
- I. Ronald N. Horowitz, M.D., for material in 10 CFR 31.11 and chromium-51 for in-vitro studies.
- J. Mark A. Rynties, M.D., for material in 10 CFR 35.200, 35.300, 35.500 and 31.11.
- K. Kenneth R. Stone, Ph.D., for material in 10 CFR 31.11 and phosphorus-32 for in-vitro studies.
- L. Michael V. Ouimette, M.D., for material in 10 CFR 35.100, 35.200, 35.300, and 31.11.
- M. Jerome F. Cordes, M.D., for material in 10 CFR 35.100, 35.200, 35.300 and 31.11.
- N. Cassandra S. Foens, M.D., for material in 10 CFR 35.300, 35.400 and 35.500.
- O. Stephen D. Chapman, D.O., for material in 10 CFR 35.100, 35.200, 35.300 and 31.11.

COPY

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number
21-01430-01

Docket or Reference number
030-02009

Amendment No. 63

13. Pursuant to Title 10, Chapter 1, Code of Federal Regulations, Part 40, "Domestic Licensing of Source Material," the licensee is authorized to possess, use, transfer, and import up to 999 kilograms of depleted uranium contained as shielding material in the molybdenum-99/technetium-99m generators authorized by this license.
14. The licensee shall maintain records of information important to safe and effective decommissioning at 1215 E. Michigan Avenue, Lansing, Michigan per the provisions of 10 CFR 30.35(g) until this license is terminated by the Commission.
15. This license is based on the licensee's statements and representations listed below:
 - A. Applications dated April 11, 1988; and
 - B. Letters dated March 23, 1989, October 17, 1989 and April 4, 1991.

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date Nov. 2, 1992

By

Peter J. Lee
Materials Licensing Section, Region III

COPY

BETWEEN:

LICENSE FEE MANAGEMENT BRANCH, ARM
AND
REGIONAL LICENSING SECTIONS

(FOR LFMS USE)
INFORMATION FROM LTS

PROGRAM CODE: 02120
STATUS CODE: 0
FEE CATEGORY: 7C
EXP. DATE: 19940630
FEE COMMENTS: CODE 23
DECOM FIN ASSUR REQD: N

LICENSE FEE TRANSMITTAL

A. REGION III

1. APPLICATION ATTACHED
APPLICANT/LICENSEE: EDWARD W. SPARROW HOSPITAL
RECEIVED DATE: 921013
DOCKET NO: 3002009
CONTROL NO.: 394140
LICENSE NO.: 21-01430-01
ACTION TYPE: AMENDMENT

2. FEE ATTACHED
AMOUNT: 466.00
CHECK NO.: 239177

3. COMMENTS

SIGNED
DATE

Deborah Horsey
11-15-92

B. LICENSE FEE MANAGEMENT BRANCH (CHECK WHEN MILESTONE 03 IS ENTERED 1/1)

1. FEE CATEGORY AND AMOUNT: 7c \$466

2. CORRECT FEE PAID. APPLICATION MAY BE PROCESSED FOR:
AMENDMENT ✓
RENEWAL _____
LICENSE _____

3. OTHER _____

SIGNED
DATE

Kita Jacques
11/15/92

RECEIVED

OCT 23 1992

REGION III

95 11 61 100 110



Department of Radiology
Radiation Oncology of Mid-Michigan, P.C.
Radiation Oncology Division
Telephone: (517) 483-2318
J. Clyde Spencer, M.D., FACP
Chairman, Radiology

October 9, 1992

David A. Krause, M.D.
Radiation Oncologist
James G. Horman, M.D., FCRP(C)
Radiation Oncologist
Cassandra Foens, M.D.
Radiation Oncologist

Subhash C. Sharma, Ph.D.
Director, Medical Physics
Martin Johnson, M.S.
Medical Physicist

United States Nuclear Regulatory Commission
Region III, Materials and Licensing Section
799 Roosevelt Road
Glen Ellyn, Illinois 60137

SUB: Amendment to our License No. 21-01430-01

Dear Sir/Madam:

We would like to amend License No. 21-01430-01 to add the following individuals as authorized users:

- A. 1. Cassandra Foens, M.D., as an authorized user on the license as she is ABR board certified. Completed exhibits 2 and 3 are enclosed. We are requesting that she be approved for group 35.300, 35.400, 35.500.
2. Stephen D. Chapman, D., as an authorized user on the license as he is board certified. Exhibits 2 and 3 are enclosed. We are requesting that he be approved for 35.100, 35.200, 35.300, and 31.11.
- B. Also please delete item J, Ghayas Uddin, M.D., from the license as he is no longer working at Sparrow Hospital.
- C. Please correct the name (item D). The correct name is Lawrence R. Simson, M.D.

An amendment fee check of \$460.00 is also enclosed.

Thank you very much for your attention to this matter. If you have any questions, please call me at 517-483-2096.

Sincerely,

Subhash Sharma
Subhash C. Sharma, Ph.D.
Radiation Safety Officer

jm

Enclosures

cc: D.A. Swan, Sr. Vice President & COO
D.A. Krause, M.D., Chairman, RSC

Log	Oct 9 11
Reletter	
Check No.	289677
Amount	\$460
Fee Category	7C
Type of Fee	Ampl
Date Check Rec'd.	10/19
Date Completed	10/19
By	Kg

PM: 10-12-92

RECEIVED

CONTROL NO.

94140

OCT 14 1992

REGION III

The American Board of Radiology

2301 W. Big Beaver Rd., Suite 625
Troy, Michigan 48064
(313) 643-0300

June 9, 1992


35755 IR 17 322
CASSANDRA SUE FOENS MD
374 WESTGATE, #9
IOWA CITY, IA 52246 ✓

DEAR DOCTOR FOENS:

I am pleased to inform you that you passed the oral examination. The American Board of Radiology voted on June 4, 1992 to grant you its certificate in RADIATION ONCOLOGY.

With personal congratulations, I am

Sincerely yours,


Kenneth L. Krabbenhoft, M.D.
Executive Director

IMPORTANT INFORMATION

1. Please return the enclosed "Request for Certificate Card" to the Board Office IMMEDIATELY. Delivery of certificates will take approximately 3-4 months.
2. Your name will be included in a Directory published by the American Board of Medical Specialties unless you specify otherwise in writing to the ABMS.
3. It is your responsibility to notify your local and state medical organizations of your certification.

CONTROL NO.

94140

The American Board of Radiology

*Organized through the cooperation of the
American College of Radiology, the American Roentgen Ray Society,
the American Radium Society, the Radiological Society of North America,
the Section on Radiology of the American Medical Association,
the American Society for Therapeutic Radiology and Oncology,
and the Association of University Radiologists*

Thereby certifies that

Martin William Johnson, M.S.

*Has pursued an accepted course of graduate study
and clinical work, has met certain standards and qualifications and
has passed the examinations conducted under the authority of*

The American Board of Radiology

On this seventh day of June, 1930

*Thereby demonstrating to the satisfaction of the Board
that he is qualified to practice the specialty of*

Therapeutic Radiological Physics

Robert G. Parner
President

Samuel L. Zuckershaft
Secretary





EXHIBIT 2
SUPPLEMENT A

SUPPLEMENT		U.S. NUCLEAR REGULATORY COMMISSION		
TRAINING AND EXPERIENCE AUTHORIZED USER OR RADIATION SAFETY OFFICER				
1. NAME OF PROPOSED AUTHORIZED USER OR RADIATION SAFETY OFFICER Cassandra Foens, MD			2. FOR PHYSICIANS, STATE OR TERRITORY WHERE LICENSED Michigan	
3. CERTIFICATION				
SPECIALTY BOARD A	CATEGORY B		MONTH AND YEAR CERTIFIED C	
American Board of Radiology	Radiation Oncology		June, 1992	
4. TRAINING RECEIVED IN BASIC RADIOISOTOPE HANDLING TECHNIQUES				
FIELD OF TRAINING A	LOCATION AND DATE(S) OF TRAINING B		TYPE AND LENGTH OF TRAINING	
			CLOCK HOURS IN LECTURE OR LABORATORY	CLOCK HOURS OF SUPERVISED ON-THE-JOB EXPERIENCE
a. RADIATION PHYSICS AND INSTRUMENTATION	7/1/78 - 6/30/92 University of Iowa Iowa City, IA 52242		210	20
b. RADIATION PROTECTION	same		30	20
c. MATHEMATICS PERTAINING TO THE USE AND MEASUREMENT OF RADIOACTIVITY	same		30	---
d. RADIATION BIOLOGY	same		135	---
e. RADIOPHARMACEUTICAL CHEMISTRY	same		10	5
5. EXPERIENCE WITH RADIATION. (Actual use of Radioisotope or Equivalent Experience)				
ISOTOPE	PCS USED AT ONE TIME	LOCATION	CLOCK HOURS	TYPE OF USE
Cs-137	67 patients	Gyn malignancies	2900 hours	intracavitary
Cs-137	1 patient	Tongue	43 hours	interstitial
I-125	2 patients	Brain	267 hours	interstitial
Ir-192	11 patients	Lung, Gyn, GI	918 hours	interstitial
P-32	3 patients	Intraperitoneal, Brain	5 hours	interstitial
I-131	3 patients	Thyroid	5 hours	oral

**EXHIBIT 3
SUPPLEMENT B**

SUPPLEMENT		U. S. NUCLEAR REGULATORY COMMISSION	
PRECEPTOR STATEMENT			
Supplement B must be completed by the applicant physician's preceptor. If more than one preceptor is necessary to document experience, add in a separate statement from each.			
1. PROPOSED PHYSICIAN USER'S NAME AND ADDRESS <hr/> FULL NAME <p align="center">Cassandra Foens, MD</p> <hr/> STREET ADDRESS <p align="center">Radiation Oncology Division Sparrow Hospital 1215 E Michigan Ave Lansing, MI 48909</p>		KEY TO COLUMN C PERSONAL PARTICIPATION SHOULD CONSIST OF: 1- Supervised examination of patients to determine the suitability for rad isotopes diagnosis and/or treatment and recommendation for prescribed dosage. 2- Collaboration in dose calibration and actual administration of dose to the patient including calculation of the radiation dose, related measurements and plotting of data. 3- Adequate period of training to enable physician to manage rad isotope patients and follow patients through diagnosis and/or course of treatment.	
2. CLINICAL TRAINING AND EXPERIENCE OF ABOVE NAMED PHYSICIAN			
ISOTOPE A	CONDITIONS DIAGNOSED OR TREATED B	NUMBER OF CASES INVOLVING PERSONAL PARTICIPATION C	COMMENTS <small>(Additional information or comments may be submitted in duplicate or separate sheets.)</small> D
	Thyroid scan		
	Thyroid uptake		
	Lung perfusion scan		
	Xenon ventilation study		
	Aerosol ventilation scan		
	Renal flow scan		
	Brain scan		
	Liver/spleen scan		
	Bone scan		
	Gastroesophageal study		
	LeVeen shunt study		
	Cystogram		
	Decryocystogram		
	Cardiac perfusion scan		
	Cardiac stress ventriculogram		
Cardiac rest ventriculogram			
Gallium scan			

EXHIBIT 3 (Continued)

PROPOSED PHYSICIAN USER Cassandra Foens, MD			
PRECEPTOR STATEMENT (Continued)			
2. CLINICAL TRAINING AND EXPERIENCE OF ABOVE NAME'D PHYSICIAN (Continued)			
ISOTOPE A	CONDITIONS DIAGNOSED OR TREATED B	NUMBER OF CASES INVOLVING PERSONAL PARTICIPATION C	COMMENTS <i>(Additional information or comments may be submitted in duplicate on separate sheets.)</i> D
P-32 <i>(See table)</i>	TREATMENT OF POLYCYTHEMIA VERA, LEUKEMIA, AND BONE METASTASES		<i>10-6-92</i> <i>9-1-92</i> <i>08</i>
P-32 <i>(See table)</i>	INTRACAVITARY TREATMENT	3	
I-131	TREATMENT OF THYROID CARCINOMA	5 3-4-6	
	TREATMENT OF HYPERTHYROIDISM	5 11	
Au-198	INTRACAVITARY TREATMENT		
Co-60 or Ca-137	INTERSTITIAL TREATMENT	1	
	INTRACAVITARY TREATMENT	67	
I-125 or Ir-192	INTERSTITIAL TREATMENT	18	
	TELE THERAPY TREATMENT	150	
Sr-90	TREATMENT OF EYE DISEASE		
	RADIOPHARMACEUTICAL PREPARATION		
Mo-99/ Tc-99m	GENERATOR		
Sr-90/ Y-90	GENERATOR		
Tc-99m	REAGENT KITS		
Other			
3. DATES AND TOTAL NUMBER OF HOURS RECEIVED IN CLINICAL RADIOISOTOPE TRAINING			
LOCATION		DATES	CLOCK HOURS OF EXPERIENCE
University of Iowa Hospital Iowa City, IA 52242		7/1/88-6/30/92	over 300 hours in didactic sessions and 3000 hours clinical
4. THE TRAINING AND EXPERIENCE INDICATED ABOVE WAS OBTAINED UNDER THE SUPERVISION OF:		5. PRECEPTOR'S SIGNATURE	
a. NAME OF SUPERVISOR David H Hussey, MD			
b. NAME OF INSTITUTION University of Iowa			
c. MAILING ADDRESS 200 Hawkins Drive		7. PRECEPTOR'S NAME (Please type or print)	
d. CITY Iowa City, IA 52242		David H Hussey, MD	
6. MATERIALS LICENSE NUMBER(S) 0037-1-52-AAB Broad License 0037-3-52-TTH Teletherapy License		8. DATE 6-16-92	

**EXHIBIT 2
SUPPLEMENT A**

SUPPLEMENT		U.S. NUCLEAR REGULATORY COMMISSION		
TRAINING AND EXPERIENCE AUTHORIZED USER OR RADIATION SAFETY OFFICER				
1. NAME OF PROPOSED AUTHORIZED USER OR RADIATION SAFETY OFFICER Stephen D. Chapman, D.O.		2. FOR PHYSICIANS, STATE OR TERRITORY WHERE LICENSED Michigan		
3. CERTIFICATION				
SPECIALTY BOARD A	CATEGORY B	MONTH AND YEAR CERTIFIED C		
Diagnostic Radiology		See Attached		
4. TRAINING RECEIVED IN BASIC RADIOISOTOPE HANDLING TECHNIQUES				
FIELD OF TRAINING A	LOCATION AND DATE(S) OF TRAINING B	TYPE AND LENGTH OF TRAINING		
		CLOCK HOURS IN LECTURE OR LABORATORY	CLOCK HOURS OF SUPERVISED ON-THE-JOB EXPERIENCE	
1. RADIATION PHYSICS AND INSTRUMENTATION	Michigan State University College of Osteopathic Medicine Residency	40	100	
2. RADIATION PROTECTION	In Diagnostic Radiology 7-1-87 - 6-30-91 East Lansing, Michigan	40	100	
3. MATHEMATICS PERTAINING TO THE USE AND MEASUREMENT OF RADIOACTIVITY	AOCR Radiation Safety and Protection	40	100	
4. RADIATION BIOLOGY	Radiobiology Course 2/88, 2/90 Chicago, Ill.	40	100	
5. RADIOPHARMACEUTICAL CHEMISTRY		40	100	
5. EXPERIENCE WITH RADIATION. (Actual use of Radioisotopes or Equivalent Experience)				
ISOTOPE	PCI USED AT ONE TIME	LOCATION	CLOCK HOURS	TYPE OF USE
SEE ATTACHED ADDENDUM				

SUPPLEMENT A

ADDENDUM

5. EXPERIENCE WITH RADIATION. (Actual use of Radioisotopes or Equivalent Experience)

<u>ISOTOPE</u>	<u>mCi USED AT ONE TIME</u>	<u>LOCATION</u>	<u>CLOCK HOURS</u>	<u>TYPE OF USE</u>
99 m Tc-AC/SC	5 mCi	MSU-Diagnostic Rad.		
" Gluco	20 mCi	Residency from	500	Diagnostic
" DTPA	20 mCi	7-1-87 - 6-30-91		
" MDP	20 mCi	Including 6 months		
" DIS10A	5 mCi	training dedicated		
" Na ₂ O ₄	17mCi, 30 mCi	to Nuclear Medicine		
" MAA	5 mCi			
" PYP	15 mCi			
135 Xe	15 mCi			
201 Tl	3 mCi			
67 Ga	6 mCi			
111 In	500 mCi			
123I	.3 mCi			

**EXHIBIT 3
SUPPLEMENT B**

SUPPLEMENT		U. S. NUCLEAR REGULATORY COMMISSION	
PRECEPTOR STATEMENT			
<i>Supplement B must be completed by the applicant physician's preceptor. If more than one preceptor is necessary to document experience, obtain a separate statement from each.</i>			
1. PROPOSED PHYSICIAN USER'S NAME AND ADDRESS <div style="border: 1px solid black; padding: 2px; margin-top: 5px;"> FULL NAME Stephen Daniel Chapman, D.O. </div> <div style="border: 1px solid black; padding: 2px; margin-top: 5px;"> STREET ADDRESS 1215 East Michigan Avenue </div> <div style="display: flex; justify-content: space-between; border: 1px solid black; padding: 2px; margin-top: 5px;"> <div style="border-right: 1px solid black; padding: 0 5px;">CITY Lansing,</div> <div style="border-right: 1px solid black; padding: 0 5px;">STATE MI</div> <div style="padding: 0 5px;">ZIP CODE 48909</div> </div>		KEY TO COLUMN C PERSONAL PARTICIPATION SHOULD CONSIST OF: 1-Supervised examination of patients to determine the suitability for radioisotope diagnosis and/or treatment and recommendation for prescribed dosage. 2-Collaboration in dose calibration and actual administration of dose to the patient including calculation of the radiation dose, related measurements and plotting of data. 3-Adequate period of training to enable physician to manage radioactive patients and follow patients through diagnosis and/or course of treatment.	
2. CLINICAL TRAINING AND EXPERIENCE OF ABOVE NAMED PHYSICIAN			
ISOTOPE <small>A</small>	CONDITIONS DIAGNOSED OR TREATED <small>B</small>	NUMBER OF CASES INVOLVING PERSONAL PARTICIPATION <small>C</small>	COMMENTS <small>(Additional information or comments may be submitted in duplicate on separate sheets.)</small> <small>D</small>
X	Thyroid scan	90	
	Thyroid uptake	76	
	Lung perfusion scan	89	
	Xenon ventilation study	56	
	Aerosol ventilation scan	26	
	Renal flow scan	53	
	Brain scan	13	
	Liver/spleen scan	69	
	Bone scan	340	
	Gastroesophageal study	24	
	LeVein shunt study	2	
	Cystogram	18	
	Decryocystogram	--	
	Cardiac perfusion scan.	260	
	Cardiac stress ventriculogram	26	
	Cardiac rest ventriculogram	18	
	Gallium scan	25	

EXHIBIT 3 (Continued)

PROPOSED PHYSICIAN USER			
Stephen D. Chapman, D.O.			
PRECEPTOR STATEMENT (Continued)			
2. CLINICAL TRAINING AND EXPERIENCE OF ABOVE NAMED PHYSICIAN (Continued)			
ISOTOPE	CONDITIONS DIAGNOSED OR TREATED	NUMBER OF CASES INVOLVING FURNISHED PORTIONATION	COMMENTS (Additional information or experience may be submitted at discretion of supervisor on back of form.)
A	B	C	D
A-32 (Sodium)	TREATMENT OF POLYCYTHEMIA VERA, LEUKEMIA, AND BONE METASTASES		
A-32 (Colloid)	INTRACAVITARY TREATMENT		
I-125	TREATMENT OF THYROID CARCINOMA	3	
	TREATMENT OF HYPERTHYROIDISM	10	
Au-198	INTRACAVITARY TREATMENT		
Co-60 or Co-137	ORTHO RECTAL TREATMENT		
	INTRACAVITARY TREATMENT		
I-125 or Ir-192	INTERSTITIAL TREATMENT		
Co-60 or Co-137	TELETERAPY TREATMENT		
Sr-90	TREATMENT OF EYE DISEASE		
	RADIOPHARMACEUTICAL PREPARATION		
Na-22/ Fe-59m	GENERATOR		
Ge-68/ Ga-67	GENERATOR		
Tc-99m	REAGENT KITS		
Other			
3. DATES AND TOTAL NUMBER OF HOURS RECEIVED IN CLINICAL RADIOISOTOPE TRAINING			
LOCATION		DATES	CLOCK HOURS OF EXPERIENCE
Michigan State University College of Osteo. Med. Residency in Diagnostic Radiology R-220 Clinical Center, E. Lansing, MI 48824		7-1-87 - 6-30-91	500
4. THE TRAINING AND EXPERIENCE INDICATED ABOVE WAS OBTAINED UNDER THE SUPERVISION OF:		5. PRECEPTOR'S SIGNATURE	
a. NAME OF SUPERVISOR		<i>Frank T. Stratton D.O.</i>	
b. NAME OF INSTITUTION			
c. STREET ADDRESS		7. PRECEPTOR'S NAME (Please type or print)	
d. CITY		Frank T. Stratton, D.O.	
e. STATE/ZIP		8. DATE	
21-04074-01		8/24/92	



American Osteopathic Association

DEPARTMENT OF EDUCATION
DIVISION OF CERTIFICATION

July 24, 1992

Stephen Daniel Chapman, D.O.
2315 Beacon Hill
Lansing, MI 48906-3606

Dear Dr. Chapman:

This is to advise you that on July 14, 1992, the Board of Trustees of the American Osteopathic Association APPROVED the recommendations of the American Osteopathic Board of Radiology and the Advisory Board for Osteopathic Specialists to certify you as follows:

Diagnostic Radiology; certificate number - 0712; effective date of certification - 3/12/92

We wish to take this opportunity to congratulate you on this accomplishment.

Your effective date of certification coincides with the date on which you were notified by the American Osteopathic Board of Radiology of completion of all requirements for certification, and is verified by this letter. A certificate is presently being prepared by the American Osteopathic Board of Radiology. As soon as it has been lettered and signed by the appropriate officers it will be mailed to you by the secretary of the specialty board.

If you have questions about this action, please contact Nancy J. Schmidt at (312) 280-5845 or (800) 621-1773.

Sincerely yours,

Joseph F. Fusco, Ed.D., Secretary
Advisory Board for Osteopathic Specialists

JFF:ujjs

cc: Eugene L. Sikorski, D.O., Chairman of the Advisory Board for Osteopathic Specialists
American Osteopathic Board of Radiology
Douglas Ward, Ph.D., Director of Department of Education
Nancy J. Schmidt, Registrar/Certification Coordinator

CONTROL NO.

94140

NOV 04 1992

Edward W. Sparrow Hospital
ATTN: Subhash C. Sharma, Ph.D.
1215 East Michigan Avenue
Lansing, MI 48909-9986

Dear Mr. Sharma:

Enclosed is Amendment No. 63 to your NRC License No. 21-01430-01 in accordance with your request.

Please review the enclosed document carefully and be sure that you understand all conditions. You must conduct your program involving radioactive materials in accordance with the conditions of your NRC license, representations made in your license application, and NRC regulations. In particular, note that you must:

1. Operate in accordance with NRC regulations 10 CFR Part 19, "Notices, Instructions and Reports to Workers; Inspections," 10 CFR Part 20, "Standards for Protection Against Radiation," and other applicable regulations.
2. Possess radioactive material only in the quantity and form indicated in your license.
3. Use radioactive material only for the purpose(s) indicated in your license.
4. Notify NRC in writing of any change in mailing address.
5. Request and obtain appropriate amendment if you plan to change ownership of your organization, change locations of radioactive material, or make any other changes in your facility or program which are contrary to your license conditions or representations made in your license application and any supplemental correspondence with NRC. Any amendment request should be accompanied by the appropriate fee specified in 10 CFR Part 170.
6. Submit a complete renewal application with proper fee or termination request at least 30 days before the expiration date on your license. You will receive a reminder notice approximately 90 days before the expiration date. Possession of radioactive material after your license expires is a violation of NRC regulations.
7. Request termination of your license if you plan to permanently discontinue activities involving radioactive material prior to your expiration date.

NOV 04 1992

You will be periodically inspected by NRC. Failure to conduct your program in accordance with NRC regulations, license conditions, and representations in your license application will result in enforcement action against you in accordance with the General Policy and Procedures for NRC Enforcement Actions, 10 CFR Part 2, Appendix C.

If you have any questions or require clarification of any of the above stated information, contact us at (708) 790-5625.

Sincerely,

Original Signed By
Peter J. Lee, Ph.D.
Materials Licensing Section

Enclosure: Amendment No. 63

RIII

Lee/bt
10/ /92
Lee